Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.65 |
| ▸ | ADK | P55263 | 14/20 | 0.56 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19271869 | 1.00 | ADORA2A (0.65) | ADORA2AADKHASPINADORA3ADORA2B | |
| SCHEMBL6723537 | 1.00 | ADORA2A (0.65) | ADORA2AADKHASPINADORA3ADORA2B | |
| SCHEMBL13649996 | 1.00 | ADORA2A (0.65) | ADORA2AADKHASPINADORA3ADORA2B | |
| SCHEMBL13021352 | 1.00 | ADORA2A (0.65) | ADORA2AADKHASPINADORA3ADORA2B | |
| SCHEMBL2786078 | 1.00 | ADORA2A (0.65) | ADORA2AADKHASPINADORA3ADORA2B | |
| SCHEMBL12716058 | 1.00 | ADORA2A (0.65) | ADORA2AADKHASPINADORA3ADORA2B | |
| SCHEMBL13650003 | 1.00 | ADORA2A (0.65) | ADORA2AADKHASPINADORA3ADORA2B | |
| SCHEMBL15241432 | 1.00 | ADORA2A (0.65) | ADORA2AADKHASPINADORA3ADORA2B | |
| SCHEMBL13091999 | 1.00 | ADORA2A (0.65) | ADORA2AADKHASPINADORA3ADORA2B | |
| SCHEMBL6723371 | 0.91 | ADK (0.65) | ADORA2AADKHASPINADORA3MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10294262-B2 | 7-deazapurine nucleosides for therapeutic uses | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2019-05-21 | — | — | US | disclosed |
| US-20170240584-A1 | NOVEL 7-DEAZAPURINE NUCLEOSIDES FOR THERAPEUTIC USES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR,V.V.I. (CZ) | 2017-08-24 | — | — | US | disclosed |
| US-9624257-B2 | 7-deazapurine nucleosides for therapeutic uses | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ASCR, V.V.I. (CZ) | 2017-04-18 | — | — | US | disclosed |
| US-20160318970-A1 | NOVEL 7-DEAZAPURINE NUCLEOSIDES FOR THERAPEUTIC USES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ASCR, V.V.I. (CZ) | 2016-11-03 | — | — | US | disclosed |
| US-9321800-B2 | 7-deazapurine nucleosides for therapeutic uses | GILEAD SCIENCES, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20150218201-A1 | NOVEL 7-DEAZAPURINE NUCLEOSIDES FOR THERAPEUTIC USES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2015-08-06 | — | — | US | disclosed |
| EP-2421879-B1 | NOVEL 7-DEAZAPURINE NUCLEOSIDES FOR THERAPEUTIC USES | ACAD OF SCIENCE CZECH REPUBLIC (CZ) | 2013-09-04 | — | — | EP | disclosed |
| US-20110306573-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF VIRAL POLYMERASES | MERCK SHARP & DOHME CORP. | 2011-12-15 | — | — | US | disclosed |
| EP-2324043-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF VIRAL POLYMERASES | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. (IT) | 2011-05-25 | — | — | EP | disclosed |
| EP-2195326-B1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF VIRAL POLYMERASES | ANGELETTI P IST RICHERCHE BIO (IT) | 2011-04-13 | — | — | EP | disclosed |
| EP-1682564-A1 | METHODS FOR PREPARING 7-(2 -SUBSTITUTED-s-D-RIBOFURANO SYL)-4-(NR2R3)-5-(SUBSTITUTED ETHYN-1-YL)-PYRROLO 2,3-D|PYRIMIDINE DERIVATIVES | GENELABS TECHNOLOGIES, INC. (US) | 2006-07-26 | — | — | EP | disclosed |
| EP-1680436-A1 | NUCLEOSIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2006-07-19 | — | — | EP | disclosed |
| US-20060079468-A1 | Nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. | 2006-04-13 | — | — | US | disclosed |
| US-20050215510-A1 | Methods for preparing 7-(2'-substituted-beta-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives | GENELABS TECHNOLOGIES, INC. | 2005-09-29 | — | — | US | disclosed |
| US-20050215511-A1 | Nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. | 2005-09-29 | — | — | US | disclosed |
| WO-2005044835-A1 | METHODS FOR PREPARING 7-(2'-SUBSTITUTED-ß-D-RIBOFURANOSYL)-4-(NR2R3)-5-(SUBSTITUTED ETHYN-1-YL)-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | GENELABS TECHNOLOGIES, INC. (US) | 2005-05-19 | — | — | WO | disclosed |
| US-20050107312-A1 | Nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2005042556-A1 | NUCLEOSIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| US-20050101550-A1 | Nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. | 2005-05-12 | — | — | US | disclosed |
| US-20050090463-A1 | Nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090463-A1 | Nucleoside compounds for treating viral infections | PNP, HAVCR2, SAMHD1 | ADORA2A 235/4885ADK 190/4885HASPIN 2576/4885 |
| US-20150218201-A1 | NOVEL 7-DEAZAPURINE NUCLEOSIDES FOR THERAPEUTIC USES | TPMT, TYMP, ENTPD5 | ADORA2A 54/4885ADK 272/4885HASPIN 2195/4885 |
| US-10294262-B2 | 7-deazapurine nucleosides for therapeutic uses | TPMT, TYMP, ENTPD5 | ADORA2A 46/4885ADK 221/4885HASPIN 2077/4885 |
| US-20050107312-A1 | Nucleoside compounds for treating viral infections | PNP, HAVCR2, SAMHD1 | ADORA2A 235/4885ADK 190/4885HASPIN 2576/4885 |
| US-20060079468-A1 | Nucleoside compounds for treating viral infections | PNP, HAVCR2, SAMHD1 | ADORA2A 235/4885ADK 190/4885HASPIN 2576/4885 |
| US-20050215510-A1 | Methods for preparing 7-(2'-substituted-beta-D-ribofuranosyl)-4-(NR2R3)-5-(substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine derivatives | HAVCR2, NR4A3, NR2C2 | ADORA2A 738/4885ADK 2532/4885HASPIN 4173/4885 |
| US-20050215511-A1 | Nucleoside compounds for treating viral infections | PNP, HAVCR2, SAMHD1 | ADORA2A 235/4885ADK 190/4885HASPIN 2576/4885 |
| US-20160318970-A1 | NOVEL 7-DEAZAPURINE NUCLEOSIDES FOR THERAPEUTIC USES | TPMT, TYMP, ENTPD5 | ADORA2A 53/4885ADK 265/4885HASPIN 2170/4885 |
| US-20170240584-A1 | NOVEL 7-DEAZAPURINE NUCLEOSIDES FOR THERAPEUTIC USES | TPMT, TYMP, ENTPD5 | ADORA2A 54/4885ADK 272/4885HASPIN 2195/4885 |
| US-20110306573-A1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF VIRAL POLYMERASES | POLR2E, POLR2H, POLRMT | ADORA2A 1395/4885ADK 762/4885HASPIN 3157/4885 |
| US-20050101550-A1 | Nucleoside compounds for treating viral infections | PNP, HAVCR2, SAMHD1 | ADORA2A 235/4885ADK 190/4885HASPIN 2576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.